A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-06
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT04951154
- Locations
- 🇺🇸
Medstar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
- Conditions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-03-11
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT04948398
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
- Conditions
- Interventions
- First Posted Date
- 2021-06-23
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 453
- Registration Number
- NCT04936308
- Locations
- 🇺🇸
Unity Health-White County Medical Center, Searcy, Arkansas, United States
🇺🇸Clinical Research Center of Connecticut, Danbury, Connecticut, United States
🇺🇸Bay Pines VA Healthcare System, Bay Pines, Florida, United States
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 405
- Registration Number
- NCT04929210
- Locations
- 🇬🇪
LTD Helsicore, Tbilisi, Georgia
🇬🇪Ltd New Hospitals, Tbilisi, Georgia
🇬🇪TSMU The First University Clinic, Tbilisi, Georgia
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 650
- Registration Number
- NCT04923893
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸Norton Cancer Institute, Louisville, Kentucky, United States
A Study of JNJ-69095897 in Healthy Participants
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 48
- Registration Number
- NCT04920578
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
- Conditions
- Interventions
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 163
- Registration Number
- NCT04919512
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Urological Associates of Southern Arizona, P.C., Tucson, Arizona, United States
🇺🇸UAMS Winthrop P. Rockefeller Cancer Institute, Little Rock, Arkansas, United States
A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 327
- Registration Number
- NCT04914429
- Locations
- 🇨🇳
Beijing Tongren Hospital, CMU, Beijing, China
🇨🇳Xiangya Hospital Central South University, Changsha, China
🇨🇳Shanghai Ruijin Hospital, Shanghai, China
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2023-02-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04911543
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 5
- Registration Number
- NCT04906980
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore